The selective estrogen receptor modulator (SERM) tamoxifen (TAM)3 and selective estrogen receptor down-regulator (SERD) fulvestrant4 are the major endocrine therapy drugs for breast cancer patients in early stages. Here, ESR1 is linked to breast carcinoma.